Phase 3 Clinical Trials With Primary Completion Dates in April 2022

This is a list of Phase 3 trials with primary completion dates in April 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ASND Ascendis Pharma A/S 2022-04-01 Phase 3 NCT04326374 Safety, Tolerability and Efficacy of TransCon hGH Weekly Versus Daily hGH in Chinese Pediatric Growth Hormone Deficiency
CANF Can-Fite BioPharma Ltd. 2022-04-01 Phase 3 NCT03168256 CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis
DBVT DBV Technologies S.A. 2022-04-01 Phase 3 NCT03211247 Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
GKOS Glaukos Corporation 2022-04-01 Phase 3 NCT03519386 Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
GLYC GlycoMimetics, Inc. 2022-04-01 Phase 3 NCT03616470 Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia
KOD Kodiak Sciences Inc. 2022-04-01 Phase 3 NCT04592419 A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
KRTX Karuna Therapeutics, Inc. 2022-04-01 Phase 3 NCT04659161 A Study to Assess Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Adult Patients With Schizophrenia (EMERGENT-2)
MCRB Seres Therapeutics, Inc. 2022-04-01 Phase 3 NCT03183141 ECOSPOR IV: Open-Label Study, Including Study SERES-012 Extension, Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
NEPH Nephros, Inc. 2022-04-01 Phase 3 NCT03534284 Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis
OBSV ObsEva SA 2022-04-01 Phase 3 NCT04335591 Extension to Study on Efficacy and Safety of Linzagolix for the Treatment of Endometriosis-associated Pain (EDELWEISS 6)
RIGL Rigel Pharmaceuticals, Inc. 2022-04-01 Phase 3 NCT04629703 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects
RIGL Rigel Pharmaceuticals, Inc. 2022-04-01 Phase 3 NCT03764618 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA